Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update
Can-Fite BioPharma Ltd. rallied in premarket trading Friday after reporting a Japanese patent allowance for Namodenoson targeting obesity. The move was strong but volume stood out as cleaner signal, with a late MarketWatch quote putting the ADR at $3.44 by 8:54 a.m. EDT, up 50 cents or 16.99%. Volume print was 21.73 million shares before the open. NYSE American’s regular trading starts at 9:30 a.m. ET, and June 26 is not shown as a 2026 U.S. equity-market holiday. That premarket volume ran more than 45 times the 65-day average of 477,200 shares and over 300 times Thursday’s regular session volume of 63,480 shares. Shares finished Thursday at $2.94, off 1.67%.